111 related articles for article (PubMed ID: 19218628)
1. [Costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up].
Harangozó J; Slezák A; Borsos K; Németh O; Csukly G
Psychiatr Hung; 2008; 23(6):464-71. PubMed ID: 19218628
[TBL] [Abstract][Full Text] [Related]
2. [Costs related to change to amisulpride in patients suffering from schizophrenia].
Harangozó J; Slezák A; Kukla B; Borsos K; Németh O
Neuropsychopharmacol Hung; 2004 Oct; 6(3):121-6. PubMed ID: 15816302
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Lin CH; Wang FC; Lin SC; Huang YH; Chen CC; Lane HY
Int Clin Psychopharmacol; 2013 Sep; 28(5):267-74. PubMed ID: 23778382
[TBL] [Abstract][Full Text] [Related]
5. Switching antipsychotic medications: general recommendations and switching to amisulpride.
Burns T; Chabannes JP; Demyttenaere K
Curr Med Res Opin; 2002; 18(4):201-8. PubMed ID: 12201620
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
Chabannes JP; Pelissolo A; Farah S; Gerard D
Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
[TBL] [Abstract][Full Text] [Related]
7. [Medico-economic assessment of neuroleptics in schizophrenia. Amisulpride versus haloperidol].
Souêtre E; Martin P; Lecanu JP; Alexandre L; Lozet H; Gauthier JM; Camus C
Encephale; 1992; 18(3):263-9. PubMed ID: 1363727
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride: a review of its use in the management of schizophrenia.
McKeage K; Plosker GL
CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.
Men P; Yi Z; Li C; Qu S; Xiong T; Yu X; Zhai S
BMC Psychiatry; 2018 Sep; 18(1):286. PubMed ID: 30185173
[TBL] [Abstract][Full Text] [Related]
12. Switching to amisulpride.
Peuskens J
Curr Med Res Opin; 2002; 18 Suppl 3():s23-8. PubMed ID: 12418609
[TBL] [Abstract][Full Text] [Related]
13. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].
Rzewuska M; Kuczyński W; Luks M
Psychiatr Pol; 2004; 38(3):453-68. PubMed ID: 15199655
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
17. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
Leucht S; Winter-van Rossum I; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE
Schizophr Bull; 2015 May; 41(3):549-58. PubMed ID: 25786408
[TBL] [Abstract][Full Text] [Related]
18. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
Zink M; Knopf U; Henn FA; Thome J
Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
[TBL] [Abstract][Full Text] [Related]
19. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
Burns T; Bale R
J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
Pélissolo A; Krebs MO; Olié JP
Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
